Virus stem bar

Blood stem cell transplants have provided lifechanging treatments to individuals. The personal journeys of Evangelina Padilla-Vaccaro , Evie Junior , and Brenden Whittaker speak volumes for the potential this treatment holds. In these trials, defective blood stem cells from the patient are corrected outside the body and then returned to the patient in a transplant procedure.

Unfortunately, there is still a certain degree of risk that accompanies this procedure. This leaves the patient temporarily without an immune system and at risk for a life-threatening viral infection. Pulsipher and his team are using virus-specific T cells VSTs , a special type of cell that plays an important role in the immune response, to treat immunosuppressed or immune deficient patients battling life-threatening viral infections.

Importantly, there was a clear positive trend associating EBV infection to transfusion volume. Abstract Background: Blood safety warrants strict screening measures to minimize the risk of transmitting blood-borne pathogens.

Publication types Research Support, Non-U. Epub Aug 6 doi: Fisetin inhibits migration, invasion and epithelial-mesenchymal transition of LMP1-positive nasopharyngeal carcinoma cells. Epub Dec 2 doi: Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study. Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients.

See all 9. Epub Jun 2 doi: Comprehensive profiling of virus microRNAs of Epstein-Barr virus-associated gastric carcinoma: highlighting the interactions of ebv-Bart9 and host tumor cells. While the patient had a transient improvement with reduced fever and reduction of the viral load, pancytopenia persisted.

The authors concluded that the effect of these therapies was very limited. Matched related myeloablative 27 , 28 , matched related nonmyeloablative 29 , 30 , 31 , matched unrelated myeloablative 31 , 32 , and cord blood stem cell transplants 33 , 34 have all been reported to be successful in case reports of CAEBV.

It is important to note that most reports of transplantation for CAEBV are case reports describing one or a few patients, and as such often report successful cases. In the largest series from a single institution, 8 of 15 patients with CAEBV were alive at a median followup of 40 months Seven patients died at a median of 3 months after transplant; three patients died of transplant related causes, 3 died due to relapsed disease, and 1 died with encephalomyelitis.

Uehara et al. Cytotoxic chemotherapy might reduce the burden of EBV-infected lymphocytes, might kill suppressor or regulatory T cells, or might make space in the marrow for the new stem cells. Transplanted stem cells can kill the remaining EBV-infected lymphocytes and provide a new immune system capable controlling the virus.

Gotoh et al. Thus, safer alternatives to transplantation should be developed. National Center for Biotechnology Information , U. Pediatr Transplant. Author manuscript; available in PMC Jun 1. Jeffrey I. Author information Copyright and License information Disclaimer. Email: vog. Copyright notice. The publisher's final edited version of this article is available at Pediatr Transplant.

See other articles in PMC that cite the published article. References 1. Epstein-Barr virus infection. N Engl J Med. Acute progressive Epstein-Barr virus infections. Ann Rev Med.